Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 3:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 753 matching trials from the live ClinicalTrials.gov search.
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Breast Carcinoma
Interventions
Cone-Beam Computed Tomography, Hypofractionated External Beam Radiation Therapy, Questionnaire Administration, Radiation Boost, Whole Breast Irradiation
Procedure · Radiation · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
40 Years and older · Female only
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
7
States / cities
Arcadia, California • Duarte, California • Irvine, California + 4 more
Conditions
Cancer
Interventions
protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, biopsy
Genetic · Other · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
Up to 120 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Leydig Cell Tumor, Ovarian Sarcoma, Ovarian Stromal Cancer, Pseudomyxoma Peritonei, Recurrent Cervical Cancer, Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Recurrent Primary Peritoneal Cavity Cancer, Recurrent Uterine Sarcoma, Recurrent Vaginal Cancer, Recurrent Vulvar Cancer
Interventions
stereotactic body radiation therapy, carboplatin, gemcitabine hydrochloride, laboratory biomarker analysis, pharmacogenomic studies
Radiation · Drug · Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
19 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Salivary Gland Squamous Cell Carcinoma, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IVA Salivary Gland Cancer, Stage IVA Squamous Cell Carcinoma of the Larynx, Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVA Verrucous Carcinoma of the Larynx, Stage IVA Verrucous Carcinoma of the Oral Cavity, Stage IVB Salivary Gland Cancer, Stage IVB Squamous Cell Carcinoma of the Larynx, Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVB Verrucous Carcinoma of the Larynx, Stage IVB Verrucous Carcinoma of the Oral Cavity, Stage IVC Salivary Gland Cancer, Stage IVC Squamous Cell Carcinoma of the Larynx, Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVC Squamous Cell Carcinoma of the Oropharynx, Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVC Verrucous Carcinoma of the Larynx, Stage IVC Verrucous Carcinoma of the Oral Cavity, Tongue Cancer
Interventions
lapatinib ditosylate, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Squamous Cell Carcinoma of the Hypopharynx, Metastatic Squamous Cell Carcinoma of the Larynx, Metastatic Squamous Cell Carcinoma of the Oral Cavity, Metastatic Squamous Cell Carcinoma of the Oropharynx, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma
Interventions
Carboplatin, Paclitaxel, Sorafenib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2026
U.S. locations
1
States / cities
Houston, Texas
Conditions
Head and Neck Cancer, Mucositis, Oral Complications of Radiation Therapy, Pain
Interventions
doxepin hydrochloride, placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
120
States / cities
Scottsdale, Arizona • Hartford, Connecticut • Jacksonville, Florida + 77 more
Conditions
Head and Neck Cancer
Interventions
microarray analysis, allele-specific oligonucleotide real-time quantitative polymerase chain reaction, diagnostic laboratory biomarker analysis
Genetic · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
mifepristone
Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years to 120 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
22
States / cities
Los Angeles, California • Hartford, Connecticut • New Britain, Connecticut + 19 more
Conditions
Cancer
Interventions
entinostat
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
3
States / cities
Bethesda, Maryland
Withdrawn Not applicable Interventional Accepts healthy volunteers

Assessment of the Tolerability of Dry Airflow in the Nasal Cavity During Sleep

NCT02547688
Conditions
Healthy Adults
Interventions
Nasal High Flow
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
carboplatin, docetaxel, adjuvant therapy
Drug · Procedure
Lead sponsor
Floyd & Delores Jones Cancer Institute at Virginia Mason Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Head and Neck Cancer
Interventions
cetuximab, cisplatin, intensity-modulated radiation therapy, Nab-Paclitaxel
Drug · Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
4
States / cities
Cleveland, Ohio • Dallas, Texas • Milwaukee, Wisconsin
Conditions
Chemotherapeutic Agent Toxicity, Endometrial Adenocarcinoma, Fallopian Tube Carcinoma, Gastrointestinal Complication, Malignant Ovarian Mixed Epithelial Tumor, Neurotoxicity Syndrome, Ovarian Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Serous Cystadenocarcinoma, Primary Peritoneal Carcinoma, Stage II Ovarian Cancer, Stage III Ovarian Cancer, Stage IV Ovarian Cancer, Undifferentiated Ovarian Carcinoma
Interventions
Paclitaxel, Cisplatin
Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
7
States / cities
Chicago, Illinois • Iowa City, Iowa • Camden, New Jersey + 4 more
Conditions
Head and Neck Cancer
Interventions
cisplatin, fluorouracil, Iressa, hyperfractionated radiation therapy
Drug · Radiation
Lead sponsor
David Adelstein
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Brenner Tumor, Fallopian Tube Cancer, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mixed Epithelial Carcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Undifferentiated Adenocarcinoma, Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer, Stage III Ovarian Epithelial Cancer, Stage IV Ovarian Epithelial Cancer
Interventions
sargramostim, paclitaxel albumin-stabilized nanoparticle formulation, laboratory biomarker analysis, immunologic technique
Biological · Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Oral Cavity Cancer
Interventions
Pembrolizumab, Patient-Specific Culture Vessel
Biological · Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Head and Neck Cancer
Interventions
chemotherapy, cisplatin, low-LET cobalt-60 gamma ray therapy, low-LET electron therapy, low-LET photon therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
459 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2013
U.S. locations
22
States / cities
Tampa, Florida • Atlanta, Georgia • Decatur, Georgia + 17 more
Conditions
Head and Neck Cancer
Interventions
EGFR antisense DNA, growth factor antagonist therapy, DC-cholesterol liposome
Biological · Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 120 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Completed Not applicable Interventional Accepts healthy volunteers Results available

Distribution of Topical Nasal Medication Within the Nasal Cavity and Sinuses by Radiographic Comparison

NCT00626366
Conditions
Chronic Sinusitis
Interventions
Sinus CT Scan, Omnipaque 240 Contrast Solution, Omnipaque 240 mg I/mL
Radiation · Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Omaha, Nebraska
Conditions
Head and Neck Cancer
Interventions
carboplatin, fluorouracil, hydroxyurea, paclitaxel, conventional surgery, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
15 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
4
States / cities
Chicago, Illinois
Conditions
Head and Neck Cancer
Interventions
porfimer sodium, Photdynamic Therapy (PDT)
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2010
U.S. locations
1
States / cities
Buffalo, New York
Conditions
Head and Neck Cancer, Lung Cancer
Interventions
filgrastim, cisplatin, paclitaxel, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2008
U.S. locations
18
States / cities
Flemington, New Jersey • Lakewood, New Jersey • Millville, New Jersey + 15 more
Conditions
Esophageal Cancer, Head and Neck Cancer, Lung Cancer
Interventions
smoking cessation intervention, nicotine
Behavioral · Drug
Lead sponsor
Personal Improvement Computer Systems
Other
Eligibility
18 Years to 67 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Reston, Virginia
Conditions
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Bevacizumab, Fosbretabulin Tromethamine, Laboratory Biomarker Analysis
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
51
States / cities
Phoenix, Arizona • Burbank, California • Concord, California + 40 more